Genzyme files Clolar in US for acute myeloid leukaemia
This article was originally published in Scrip
Executive Summary
Genzymehas filed a supplemental NDA with the US FDAfor use of Clolar (clofarabine) in previously untreated adults aged 60 years or older with acute myeloid leukaemia (AML) who have at least one unfavourable prognostic factor.